Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

Zoran Gatalica, Carrie Snyder, Todd Maney, Anatole Ghazalpour, Daniel A. Holterman, Nianqing Xiao, Peggy Overberg, Inga Rose, Gargi D. Basu, Semir Vranic, Henry T. Lynch, Daniel D. Von Hoff, Omid Hamid

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell activation facilitating disease progression. Preliminary clinical trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types. We analyzed the distribution of PD-1-positive tumor-infiltrating lymphocytes (TIL) and cancer cells' expression of PD-L1 in a molecularly profiled cohort of 437 malignancies (380 carcinomas, 33 sarcomas, and 24 melanomas). We showed that the presence of PD-1+ TILs significantly varied among cancer types (from 0% in extraskeletal myxoid chondrosarcomas to 93% in ovarian cancer), and was generally associated with the increased number of mutations in tumor cells (P = 0.029). Cancer cell expression of PD-L1 varied from absent (in Merkel cell carcinomas) to 100% (in chondro- and liposarcomas), but showed the inverse association with the number of detected mutations (P = 0.004). Both PD-1 and PD-L1 expression were significantly higher in triple-negative breast cancers (TNBC) than in non-TNBC (P <0.001 and 0.017, respectively). Similarly, MSI-H colon cancers had higher PD-1 and PD-L1 expression than the micro-satellite stable tumors (P = 0.002 and 0.02, respectively). TP53-mutated breast cancers had significantly higher PD-1 positivity than those harboring other driver mutations (e.g., PIK3CA; P = 0.002). In non-small cell lung cancer, PD-1/PD-L1 coexpression was identified in 8 cases (19%), which lacked any other targetable alterations (e.g., EGFR, ALK, or ROS1). Our study demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities.

Original languageEnglish
Pages (from-to)2965-2970
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Cell Death
Ligands
Neoplasms
Mutation
Programmed Cell Death 1 Receptor
Triple Negative Breast Neoplasms
Breast Neoplasms
Merkel Cell Carcinoma
Tumor-Infiltrating Lymphocytes
Liposarcoma
Non-Small Cell Lung Carcinoma
Sarcoma
Ovarian Neoplasms
Colonic Neoplasms
Disease Progression
Melanoma
Clinical Trials
Carcinoma
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Medicine(all)

Cite this

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. / Gatalica, Zoran; Snyder, Carrie; Maney, Todd; Ghazalpour, Anatole; Holterman, Daniel A.; Xiao, Nianqing; Overberg, Peggy; Rose, Inga; Basu, Gargi D.; Vranic, Semir; Lynch, Henry T.; Von Hoff, Daniel D.; Hamid, Omid.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 12, 01.12.2014, p. 2965-2970.

Research output: Contribution to journalArticle

Gatalica, Z, Snyder, C, Maney, T, Ghazalpour, A, Holterman, DA, Xiao, N, Overberg, P, Rose, I, Basu, GD, Vranic, S, Lynch, HT, Von Hoff, DD & Hamid, O 2014, 'Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type', Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 12, pp. 2965-2970. https://doi.org/10.1158/1055-9965.EPI-14-0654
Gatalica, Zoran ; Snyder, Carrie ; Maney, Todd ; Ghazalpour, Anatole ; Holterman, Daniel A. ; Xiao, Nianqing ; Overberg, Peggy ; Rose, Inga ; Basu, Gargi D. ; Vranic, Semir ; Lynch, Henry T. ; Von Hoff, Daniel D. ; Hamid, Omid. / Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 12. pp. 2965-2970.
@article{4f79eb38118a48ab886cfeb836c8da32,
title = "Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type",
abstract = "Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell activation facilitating disease progression. Preliminary clinical trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types. We analyzed the distribution of PD-1-positive tumor-infiltrating lymphocytes (TIL) and cancer cells' expression of PD-L1 in a molecularly profiled cohort of 437 malignancies (380 carcinomas, 33 sarcomas, and 24 melanomas). We showed that the presence of PD-1+ TILs significantly varied among cancer types (from 0{\%} in extraskeletal myxoid chondrosarcomas to 93{\%} in ovarian cancer), and was generally associated with the increased number of mutations in tumor cells (P = 0.029). Cancer cell expression of PD-L1 varied from absent (in Merkel cell carcinomas) to 100{\%} (in chondro- and liposarcomas), but showed the inverse association with the number of detected mutations (P = 0.004). Both PD-1 and PD-L1 expression were significantly higher in triple-negative breast cancers (TNBC) than in non-TNBC (P <0.001 and 0.017, respectively). Similarly, MSI-H colon cancers had higher PD-1 and PD-L1 expression than the micro-satellite stable tumors (P = 0.002 and 0.02, respectively). TP53-mutated breast cancers had significantly higher PD-1 positivity than those harboring other driver mutations (e.g., PIK3CA; P = 0.002). In non-small cell lung cancer, PD-1/PD-L1 coexpression was identified in 8 cases (19{\%}), which lacked any other targetable alterations (e.g., EGFR, ALK, or ROS1). Our study demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities.",
author = "Zoran Gatalica and Carrie Snyder and Todd Maney and Anatole Ghazalpour and Holterman, {Daniel A.} and Nianqing Xiao and Peggy Overberg and Inga Rose and Basu, {Gargi D.} and Semir Vranic and Lynch, {Henry T.} and {Von Hoff}, {Daniel D.} and Omid Hamid",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0654",
language = "English",
volume = "23",
pages = "2965--2970",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

AU - Gatalica, Zoran

AU - Snyder, Carrie

AU - Maney, Todd

AU - Ghazalpour, Anatole

AU - Holterman, Daniel A.

AU - Xiao, Nianqing

AU - Overberg, Peggy

AU - Rose, Inga

AU - Basu, Gargi D.

AU - Vranic, Semir

AU - Lynch, Henry T.

AU - Von Hoff, Daniel D.

AU - Hamid, Omid

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell activation facilitating disease progression. Preliminary clinical trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types. We analyzed the distribution of PD-1-positive tumor-infiltrating lymphocytes (TIL) and cancer cells' expression of PD-L1 in a molecularly profiled cohort of 437 malignancies (380 carcinomas, 33 sarcomas, and 24 melanomas). We showed that the presence of PD-1+ TILs significantly varied among cancer types (from 0% in extraskeletal myxoid chondrosarcomas to 93% in ovarian cancer), and was generally associated with the increased number of mutations in tumor cells (P = 0.029). Cancer cell expression of PD-L1 varied from absent (in Merkel cell carcinomas) to 100% (in chondro- and liposarcomas), but showed the inverse association with the number of detected mutations (P = 0.004). Both PD-1 and PD-L1 expression were significantly higher in triple-negative breast cancers (TNBC) than in non-TNBC (P <0.001 and 0.017, respectively). Similarly, MSI-H colon cancers had higher PD-1 and PD-L1 expression than the micro-satellite stable tumors (P = 0.002 and 0.02, respectively). TP53-mutated breast cancers had significantly higher PD-1 positivity than those harboring other driver mutations (e.g., PIK3CA; P = 0.002). In non-small cell lung cancer, PD-1/PD-L1 coexpression was identified in 8 cases (19%), which lacked any other targetable alterations (e.g., EGFR, ALK, or ROS1). Our study demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities.

AB - Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell activation facilitating disease progression. Preliminary clinical trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types. We analyzed the distribution of PD-1-positive tumor-infiltrating lymphocytes (TIL) and cancer cells' expression of PD-L1 in a molecularly profiled cohort of 437 malignancies (380 carcinomas, 33 sarcomas, and 24 melanomas). We showed that the presence of PD-1+ TILs significantly varied among cancer types (from 0% in extraskeletal myxoid chondrosarcomas to 93% in ovarian cancer), and was generally associated with the increased number of mutations in tumor cells (P = 0.029). Cancer cell expression of PD-L1 varied from absent (in Merkel cell carcinomas) to 100% (in chondro- and liposarcomas), but showed the inverse association with the number of detected mutations (P = 0.004). Both PD-1 and PD-L1 expression were significantly higher in triple-negative breast cancers (TNBC) than in non-TNBC (P <0.001 and 0.017, respectively). Similarly, MSI-H colon cancers had higher PD-1 and PD-L1 expression than the micro-satellite stable tumors (P = 0.002 and 0.02, respectively). TP53-mutated breast cancers had significantly higher PD-1 positivity than those harboring other driver mutations (e.g., PIK3CA; P = 0.002). In non-small cell lung cancer, PD-1/PD-L1 coexpression was identified in 8 cases (19%), which lacked any other targetable alterations (e.g., EGFR, ALK, or ROS1). Our study demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=84919385463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919385463&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0654

DO - 10.1158/1055-9965.EPI-14-0654

M3 - Article

VL - 23

SP - 2965

EP - 2970

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -